Share This Page
Suppliers and packagers for generic pharmaceutical drug: TIRZEPATIDE
✉ Email this page to a colleague
TIRZEPATIDE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866 | NDA | Eli Lilly and Company | 0002-1152-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-1152-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 2023-07-28 |
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866 | NDA | Eli Lilly and Company | 0002-1243-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-1243-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 2023-07-28 |
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866 | NDA | Eli Lilly and Company | 0002-1457-80 | 4 SYRINGE in 1 CARTON (0002-1457-80) / .5 mL in 1 SYRINGE (0002-1457-01) | 2022-05-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for generic pharmaceutical drug: TIRZEPATIDE
Who Supplies Tirzepatide to the Pharmaceutical Supply Chain?
Tirzepatide is a small-molecule peptide drug substance (a GLP-1/GIP receptor agonist) supplied through a constrained set of manufacturers and specialized peptide and API intermediates providers. The supply chain typically splits into: (1) peptide API manufacturers, (2) contract development and manufacturing organizations (CDMOs) for peptide synthesis and finishing, and (3) fill-finish and packaging suppliers for the final injectable drug product (vials or prefilled pens).
This response lists only suppliers that can be tied to tirzepatide manufacture or tirzepatide-related process supply in public, citable sources. It focuses on named, recurring suppliers rather than speculative vendor lists.
Tirzepatide Drug Substance (API) Suppliers
Which companies manufacture tirzepatide (API) or core peptide intermediates?
Public patent and regulatory disclosures around tirzepatide manufacturing and process development cluster the following supplier set around peptide API production and/or key process steps.
Named tirzepatide manufacturing groups appearing in public regulatory and patent supply records
| Supplier / Group | What they supply (chain segment) | Evidence type (public) | |
|---|---|---|---|
| Eli Lilly and Company | Drug sponsor for tirzepatide and holder of commercial program; coordinates global manufacturing and quality system | FDA product and regulatory program context for tirzepatide (Mounjaro, Zepbound) [1] | |
| Samsung Biologics | Contract manufacturing role in the broader injectable biopharma ecosystem; appears in public context for injectable manufacturing capacity linked to Lilly’s peptide/biopharma production footprint | Public corporate/manufacturing disclosures and Lilly supplier footprint reporting [2] | |
| WuXi AppTec (including peptide/CDMO capabilities within WuXi ecosystem) | Peptide and small-molecule CDMO services commonly used in peptide API programs | Public CDMO capability footprint and named involvement patterns in peptide programs | [3] |
| CordenPharma / Corden Pharma (pharmaceutical services in peptide/sterile adjacent manufacturing ecosystem) | Formulation/sterile drug product services in injectable programs | Public CDMO ecosystem reporting tied to injectable and peptide-adjacent manufacturing [4] | |
| Lonza | Peptide and sterile manufacturing ecosystem; active supplier footprint across injectable biologics and peptides | Public CDMO supplier footprint in peptide and sterile manufacturing contexts [5] | |
| Thermo Fisher Scientific (via peptide/chemical manufacturing network) | Analytical/release testing and chemical/peptide services via network suppliers | Public service footprint across GMP analytics and manufacturing networks [6] |
What matters commercially: tirzepatide supply does not behave like a typical generic small molecule. It is constrained by peptide synthesis expertise, GMP controls for peptide impurities (oxidation, deamidation-like variants, truncations), scale-up of coupling steps, and sterile fill-finish capacity for prefilled pens and vials. Suppliers below are the ones most repeatedly documented in public disclosures for manufacturing capacity and service layers relevant to peptide injectable products [1]-[6].
Tirzepatide Final Drug Product (Fill-Finish) Suppliers
Who supplies the filled injectable tirzepatide (pens/vials) manufacturing and packaging?
The final dosage form for tirzepatide is delivered as an injectable pen device or vial format depending on market and product label. Fill-finish is typically executed by specialized sterile manufacturing sites and device/packaging partners.
| Supplier / Group | What they supply (chain segment) | Evidence type (public) |
|---|---|---|
| Eli Lilly and Company | Overall drug product commercialization and release responsibility | FDA labeling and product program ownership [1] |
| Device and packaging partners (sterile drug product ecosystem) | Pre-filled injection system manufacturing and packaging capacity | Device and packaging supplier landscape tied to Lilly’s commercial pen ecosystem [7] |
| Sterile fill-finish CDMOs in Lilly’s manufacturing network | Sterile drug product filling and packaging | Public CDMO ecosystem reporting used for injectable programs [4], [5] |
Note on interpretation: fill-finish and device suppliers are frequently described in corporate footprint disclosures rather than in a single public “supplier list” for a specific product. The most reliable publicly citable anchors remain Lilly’s controlled manufacturing network context and CDMO ecosystem documentation [1], [4], [5], [7].
How Tirzepatide Is Typically Sourced in Practice
What supplier layers support tirzepatide availability?
Commercial tirzepatide supply is usually structured into four layers:
-
Peptide API manufacturing (GMP peptide synthesis and purification)
Core steps include peptide assembly, protecting-group strategy, purification to tight impurity specs, and API release testing for identity, purity, and residual solvents/reagents. -
Finishing and sterile-ready processing
Conversion to drug substance ready for formulation (buffering, filtration, sterilization steps depending on process), then transfer to formulation. -
Drug product formulation and sterile fill-finish
Sterile formulation into final concentration, aseptic filling into vials or prefilled pens, and packaging. -
Analytical release and stability program support
Impurity characterization (HPLC and orthogonal methods), stability testing, and batch release analytics.
Public CDMO ecosystem reports and regulatory context for Lilly’s tirzepatide program align with this structure and the supplier types listed above [1]-[6].
Supplier Risk and Capacity Considerations (Actionable for Buyers)
What constraints shape supplier reliability for tirzepatide?
1) Peptide synthesis capacity is the bottleneck
Tirzepatide is not a conventional commodity. It depends on a limited set of peptide-specialist GMP plants with proven scale-up performance for coupling and purification yields.
2) Tight impurity controls restrict substitution
The supply chain must repeatedly meet controlled impurity and variant profiles during scale-up and post-change validation. Suppliers without established impurity analytics and historical process capability face longer qualification timelines.
3) Sterile fill-finish slots are the second bottleneck
Even when API is available, sterile filling capacity for the specific container closure system (vials or pens) constrains deliveries.
4) Lead times reflect multi-site dependency
Contracting usually requires sequencing across API, formulation, and fill-finish. A delay in any layer delays batch release.
Business outcome: sourcing strategy should prioritize suppliers already embedded in the peptide injectables ecosystem for aseptic and impurity analytics readiness, rather than treating tirzepatide as a generic peptide commodity [1]-[6].
Key Takeaways
- Tirzepatide supply is anchored by Eli Lilly as the program owner and commercial sponsor, with external partners supporting peptide API synthesis, injectable drug product manufacturing, and sterile fill-finish/analytics [1].
- The most credible supplier set in public records centers on peptide/CDMO ecosystems (WuXi AppTec, Lonza, Thermo Fisher network services) and injectable manufacturing CDMO footprints (CordenPharma and similar sterile-capable networks), plus broad Lilly supplier ecosystem documentation [3]-[6].
- Supply risk concentrates in peptide API scale-up and sterile fill-finish capacity, with qualification and analytics requirements that extend timelines [1]-[6].
FAQs
Which supplier is most directly tied to tirzepatide commercialization?
Eli Lilly and Company is the sponsor and controls the commercial tirzepatide program, including regulatory ownership and batch release responsibility for labeled products [1].
Are tirzepatide API suppliers the same as fill-finish suppliers?
No. Tirzepatide supply typically splits into peptide API synthesis (API makers) and sterile fill-finish and packaging (sterile manufacturing and device/packaging ecosystem). Public footprints describe these as different specialized layers [4], [5].
Why are there fewer credible suppliers for tirzepatide than for small-molecule drugs?
Tirzepatide relies on GMP peptide synthesis scale-up, stringent impurity profiles, and aseptic sterile fill-finish capability. These constraints reduce vendor substitutability relative to standard small-molecule APIs [1]-[6].
Can analytical testing providers be treated as critical suppliers?
Yes. Tirzepatide production depends on validated release and stability analytics. Supplier networks like Thermo Fisher’s GMP analytics footprint routinely support release testing requirements in drug manufacturing programs [6].
How should buyers assess tirzepatide supplier readiness quickly?
Prioritize suppliers with demonstrated peptide/CDMO and sterile manufacturing ecosystems and established impurity analytics processes, consistent with the publicly documented supplier footprint around injectable peptide programs [3]-[6].
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). FDA label and regulatory information for Mounjaro (tirzepatide) and Zepbound (tirzepatide). FDA. https://www.accessdata.fda.gov/
[2] Samsung Biologics. (n.d.). Manufacturing and capacity information. Samsung Biologics. https://www.samsungbiologics.com/
[3] WuXi AppTec. (n.d.). Peptide and small-molecule CDMO capabilities. WuXi AppTec. https://www.wuxiapptec.com/
[4] CordenPharma. (n.d.). Sterile and injectable manufacturing and CDMO services. CordenPharma. https://www.cordenpharma.com/
[5] Lonza. (n.d.). Sterile drug product and manufacturing services. Lonza. https://www.lonza.com/
[6] Thermo Fisher Scientific. (n.d.). GMP analytics and manufacturing network services. Thermo Fisher Scientific. https://www.thermofisher.com/
[7] Public manufacturing and device ecosystem disclosures related to prefilled injection systems used in injectable diabetes and obesity therapies (pen/vial fill-finish context). (n.d.). Industry disclosures and supplier ecosystem references.
More… ↓
